

WuXi AppTec acquires HD Biosciences

10 February 2017 | News | By BioSpectrum Bureau

WuXi AppTec acquires HD Biosciences



Singapore: WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, has acquired HD Biosciences (HDB), a biology focused preclinical drug discovery and contract research organization (CRO). After completion of acquisition, HD Biosciences will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing greater services. The acquisition will further strengthen WuXi's R&D capability from target validation to lead discovery and optimization, improving and expanding WuXi's open-access enabling service platform.

"We are excited about this acquisition and the great opportunities it brings along. HD Biosciences has a long-standing mission to grow into a major global player with distinctive core competences that could create special value for our clients. Merging with WuXi AppTec, a clear industry leader in drug R&D enabling services with enormous global exposure, resources and vision, will greatly speed up the process. We are confident that the integration will elevated our services to a new height and will enable us to better meet our growing customer needs," said Dr. Xuehai Tan, Chairman and CEO, HD Biosciences.